secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ayala Pharmaceuticals, Inc. (—)
CIK:        0001797336
Form:       8-K
Filed at:   2022-11-17T23:59:59+00:00
Accession:  0001193125-22-287710
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Ayala Pharmaceuticals receives Nasdaq deficiency notices for equity <$10M and bid price below $1.00
--------------------------------------------------------------------------------

- Stockholders' equity as of Sep 30, 2022 was ~$8.16M, below Nasdaq's $10M minimum.
- Bid price closed below $1.00 for 30 consecutive business days as of Nov 16, 2022.
- Company has until Dec 27, 2022 to submit a plan for equity compliance; until May 15, 2023 for bid price.
- Options include transferring to Nasdaq Capital Market; no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1797336/000119312522287710/0001193125-22-287710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1797336/000119312522287710/d360152d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-287710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer